Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
Recruiting · Phase 2 · NCT05554302
Conditions: Brain Metastases, Brain Cancer
At a glance
- Research payments reported, 2025
- $92,997
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Baptist Health South Florida (with Blue Earth Diagnostics)
- Tested
- 18F-Fluciclovine (drug)
- Dates
- Started 2023-01-10; completion 2030-01
- Results posted
- Not yet
This study is for patients who have had surgery to remove brain metastasis and are planned to have stereotactic radiosurgery (SRS) after their brain surgery. It will be optional for patients to have a pre-surgery 18F-Fluciclovine PET/CT scan. The goal of the study is to determine whether a specific imaging agent, known as 18F-Fluciclovine, will help physicians evaluate the extent of surgery and determine if there is any visible tumor above what MRI alone can identify as well as improve the physicians' ability to detect recurring disease. This agent (18F-Fluciclovine) is investigational for the imaging of brain metastases.
From ClinicalTrials.gov, last updated 2025-12-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $92,997 in research payments for this study in 2025 (18 payments).
Products named: Axumin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Miami Cancer Institute at Baptist Health $92,997
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.